IASLC WCLC25 9/8/25 Press Briefing скачать в хорошем качестве

IASLC WCLC25 9/8/25 Press Briefing

Abstract 1428: EA5181: Phase 3 Trial of Concurrent and Consolidative Durvalumab vs Consolidation Durva Alone for Unresectable Stage 3 NSCLC, John Varlotto, M.D., from Marshall University, United States Abstract 2147: Adjuvant chemotherapy (CT) vs CT-immunotherapy for R0 stage IB-IIIA NSCLC patients (NADIM ADJUVANT): a randomised, phase 3 trial, Mariano Provencio Hospital Universitario Puerta de Hierro Majadahonda, Spain Abstract 1756 Hypofractionated vs Conventional Fractionated Radiotherapy With Concurrent Chemotherapy for LS-SCLC: A Multi-Center Phase III Trial, Nan Bi, The National Cancer Center of China/Cancer Hospital, Chinese Academy of Medical Sciences, China Abstract 3625: Survival outcome of VATS compared to open lobectomy for lung cancer: an individual patient data meta-analysis of randomised trials, Jacie Jiaqi, Law Royal Brompton Hospital, United Kingdom Abstract 757 Spread through airspaces (STAS) and patient outcomes in the phase III JCOG0802 trial of segmentectomy vs lobectomy in NSCLC, Yasushi Yatabe, National Cancer Center, Japan Abstract 2608 Comparing 74 vs 80 as the Upper Age Limit for Lung Cancer Screening: A Multi-Centre Cohort Study, Patrick Goodley, Manchester University NHS Foundation Trust, United Kingdom